Causal Foundation Models with Continuous Treatments

The harder problem buried in the summary is generalization: the model must estimate dose-response curves for treatment values it has never seen, which means errors compound in ways that binary causal models simply don't face. Whether the meta-learning signal is rich enough to handle distribution shift across genuinely different domains, say pharmacology versus labor economics, is not addressed in the summary and is the real open question.

This sits in a broader pattern of research confronting the gap between what models claim to do and what survives contact with real deployment conditions. The 'Training ML Models with Predictable Failures' paper from the same day makes a structurally similar argument: evaluation setups systematically miss failure modes that only appear in the wild. A causal foundation model that meta-learns across tasks faces exactly that risk, since the diversity of training tasks determines whether the model's priors help or mislead on unseen domains. The two papers don't cite each other, but together they frame a shared problem: generalization claims are only as good as the evaluation coverage behind them.

Watch whether any group benchmarks this model on a held-out domain, such as environmental policy or clinical dose-finding, where ground-truth causal effects are partially known from randomized data. If out-of-domain performance degrades sharply relative to in-distribution tasks, the meta-learning framing is doing less work than the paper implies.